Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

181. Life Expectancy after Myocardial Infarction, According to Hospital Performance. Full Text available with Trip Pro

Life Expectancy after Myocardial Infarction, According to Hospital Performance. Thirty-day risk-standardized mortality rates after acute myocardial infarction are commonly used to evaluate and compare hospital performance. However, it is not known whether differences among hospitals in the early survival of patients with acute myocardial infarction are associated with differences in long-term survival.We analyzed data from the Cooperative Cardiovascular Project, a study of Medicare (...) beneficiaries who were hospitalized for acute myocardial infarction between 1994 and 1996 and who had 17 years of follow-up. We grouped hospitals into five strata that were based on case-mix severity. Within each case-mix stratum, we compared life expectancy among patients admitted to high-performing hospitals with life expectancy among patients admitted to low-performing hospitals. Hospital performance was defined by quintiles of 30-day risk-standardized mortality rates. Cox proportional-hazards models

2016 NEJM

182. Sexual activity and function in the year after an acute myocardial infarction (AMI) among younger women and men in the U.S. and Spain Full Text available with Trip Pro

Sexual activity and function in the year after an acute myocardial infarction (AMI) among younger women and men in the U.S. and Spain Most younger adults who experience an acute myocardial infarction (AMI) are sexually active before the AMI, but little is known about sexual activity or sexual function after the event.To describe patterns of sexual activity and function and identify indicators of the probability of loss of sexual activity in the year after AMI.Data from the prospective

2016 JAMA cardiology

183. Opt-out Enrollment Increases Participation in a Remote Monitoring Intervention for Myocardial Infarction Patients Full Text available with Trip Pro

Opt-out Enrollment Increases Participation in a Remote Monitoring Intervention for Myocardial Infarction Patients 27603755 2018 09 17 2018 12 02 2380-6591 1 7 2016 10 01 JAMA cardiology JAMA Cardiol Participation Rates With Opt-out Enrollment in a Remote Monitoring Intervention for Patients With Myocardial Infarction. 847-848 10.1001/jamacardio.2016.2374 Mehta Shivan J SJ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia2Center for Health Incentives (...) Humans Myocardial Infarction diagnosis Patient Participation Telemedicine 2016 10 21 6 0 2018 9 18 6 0 2016 9 8 6 0 ppublish 27603755 2549969 10.1001/jamacardio.2016.2374 PMC6140334 NIHMS988329 Science. 2003 Nov 21;302(5649):1338-9 14631022 JAMA. 2004 Jun 9;291(22):2720-6 15187053 JAMA. 2007 Nov 28;298(20):2415-7 18042920

2016 JAMA cardiology

184. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. Full Text available with Trip Pro

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. To assess the association between early and prolonged β blocker treatment and mortality after acute myocardial infarction.Multicentre prospective cohort study.Nationwide French registry of Acute ST- and non-ST-elevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005.2679 consecutive patients with acute myocardial infarction and without heart failure (...) results.Early β blocker use was associated with reduced 30 day mortality in patients with acute myocardial infarction, and discontinuation of β blockers at one year was not associated with higher five year mortality. These findings question the utility of prolonged β blocker treatment after acute myocardial infarction in patients without heart failure or left ventricular dysfunction.Trial registration Clinical trials NCT00673036.Published by the BMJ Publishing Group Limited. For permission to use (where

2016 BMJ

185. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm Full Text available with Trip Pro

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk (...) of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention. We investigated the incidence of stroke, outcomes after stroke, and the efficacy of ticagrelor focusing on the approved 60 mg twice daily dose for reducing stroke in this population.Patients were followed for a median of 33 months. Stroke events were adjudicated by a central committee

2016 EvidenceUpdates Controlled trial quality: predicted high

186. An algorithm for rule-in and rule-out of acute myocardial infarction using a novel troponin I assay (Abstract)

An algorithm for rule-in and rule-out of acute myocardial infarction using a novel troponin I assay To derive and validate a hybrid algorithm for rule-out and rule-in of acute myocardial infarction based on measurements at presentation and after 2 hours with a novel cardiac troponin I (cTnI) assay.The algorithm was derived and validated in two cohorts (605 and 592 patients) from multicentre studies enrolling chest pain patients presenting to the emergency department (ED) with onset of last

2016 EvidenceUpdates

187. Comparison of In-Hospital Mortality, Length of Stay, Postprocedural Complications, and Cost of Single-Vessel Versus Multivessel Percutaneous Coronary Intervention in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction (from Nat (Abstract)

Comparison of In-Hospital Mortality, Length of Stay, Postprocedural Complications, and Cost of Single-Vessel Versus Multivessel Percutaneous Coronary Intervention in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction (from Nat The primary objective of our study was to evaluate the in-hospital outcomes in terms of mortality, procedural complications, hospitalization costs, and length of stay (LOS) after multivessel percutaneous coronary intervention (MVPCI (...) ) in hemodynamically stable patients with ST-segment elevation myocardial infarction (STEMI). The study cohort was derived from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database, years 2006 to 2012. Percutaneous coronary interventions (PCI) performed during STEMI were identified using appropriate International Classification of Diseases, Ninth Revision, diagnostic and procedural codes. Patients in cardiogenic shock were excluded. Hierarchical mixed-effects logistic regression models

2016 EvidenceUpdates

188. The Vascular Quality Initiative Cardiac Risk Index for prediction of myocardial infarction after vascular surgery Full Text available with Trip Pro

The Vascular Quality Initiative Cardiac Risk Index for prediction of myocardial infarction after vascular surgery The objective of this study was to develop and to validate the Vascular Quality Initiative (VQI) Cardiac Risk Index (CRI) for prediction of postoperative myocardial infarction (POMI) after vascular surgery.We developed risk models for in-hospital POMI after 88,791 nonemergent operations from the VQI registry, including carotid endarterectomy (CEA; n = 45,340), infrainguinal bypass

2016 EvidenceUpdates

189. Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction Full Text available with Trip Pro

Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction As a foundation for quality improvement, assessing clinical outcomes across hospitals requires appropriate risk adjustment to account for differences in patient case mix, including presentation after cardiac arrest.The aim of this study was to develop and validate a parsimonious patient-level clinical risk model of in-hospital mortality for contemporary patients with acute myocardial infarction.Patient characteristics (...) prospective risk stratification in clinical care.The in-hospital mortality rate was 4.6%. Age, heart rate, systolic blood pressure, presentation after cardiac arrest, presentation in cardiogenic shock, presentation in heart failure, presentation with ST-segment elevation myocardial infarction, creatinine clearance, and troponin ratio were all independently associated with in-hospital mortality. The C statistic was 0.88, with good calibration. The model performed well in subgroups based on age; sex; race

2016 EvidenceUpdates

190. Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. Full Text available with Trip Pro

Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. International studies report a decline in mortality following non-ST-elevation myocardial infarction (NSTEMI). Whether this is due to lower baseline risk or increased utilization of guideline-indicated treatments is unknown.To determine whether changes in characteristics of patients with NSTEMI are associated with improvements in outcomes.Data (...) on patients with NSTEMI in 247 hospitals in England and Wales were obtained from the Myocardial Ischaemia National Audit Project between January 1, 2003, and June 30, 2013 (final follow-up, December 31, 2013).Baseline demographics, clinical risk (GRACE risk score), and pharmacological and invasive coronary treatments.Adjusted all-cause 180-day postdischarge mortality time trends estimated using flexible parametric survival modeling.Among 389 057 patients with NSTEMI (median age, 72.7 years [IQR, 61.7-81.2

2016 JAMA

191. Acute myocardial infarction. (Abstract)

Acute myocardial infarction. Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends (...) , including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins. This seminar discusses the important topics of the pathophysiology, epidemiological trends, and modern management of acute myocardial infarction

2016 Lancet

192. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer Full Text available with Trip Pro

Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer Heart failure (HF) is associated with excess morbidity and mortality for which noncardiac causes are increasingly recognized. The authors previously described an increased risk of cancer among HF patients compared with community controls.This study examined whether HF was associated with an increased risk of subsequent cancer among a homogenous population of first myocardial infarction (MI) survivors.A

2016 EvidenceUpdates

193. Validation of NICE diagnostic guidance for rule out of myocardial infarction using high-sensitivity troponin tests (Abstract)

Validation of NICE diagnostic guidance for rule out of myocardial infarction using high-sensitivity troponin tests To validate the National Institute for Health and Care Excellence (NICE) recommended algorithms for high-sensitivity troponin (hsTn) assays in adults presenting with chest pain.International post hoc analysis of three prospective, observational studies from tertiary hospital emergency departments. The primary endpoint was cardiac death or acute myocardial infarction (AMI) within 24 (...)  hours of presentation, and the secondary endpoint was major adverse cardiac events (MACE) at 30 days.15% of patients were diagnosed with non-ST elevation myocardial infarction (MI) on admission. The hsTnI algorithm classified 2506/3128 (80.1%) of patients as 'ruled out' with 50 (2.0%) missed MI. 943/3128 (30.1%) of patients had a troponin I level below the limit of detection on admission with 2 (0.2%) missed MI. For the hsTnT algorithm, 1794/3374 (53.1%) of patients were 'ruled out' with 7 (0.4

2016 EvidenceUpdates

194. Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication Full Text available with Trip Pro

Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication Beta-blocker (BB) therapy after myocardial infarction (MI) reduces all-cause mortality.The aim of this study was to investigate BB dosing patterns and compliance following MI.Using medical patient files and nationwide databases, we identified 100 patients who were discharged following MI in 2012 from Aarhus University Hospital, Denmark

2016 Drugs - real world outcomes

195. Ventricular Septal Defect after Acute Myocardial Infarction. (Abstract)

Ventricular Septal Defect after Acute Myocardial Infarction. 27276580 2016 06 21 2016 11 26 1533-4406 374 23 2016 Jun 09 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Ventricular Septal Defect after Acute Myocardial Infarction. e28 10.1056/NEJMicm1512579 Rademakers Leonard M LM Catharina Hospital, Eindhoven, the Netherlands nard.rademakers@catharinaziekenhuis.nl. Van Nunen Lokien X LX Catharina Hospital, Eindhoven, the Netherlands nard.rademakers (...) @catharinaziekenhuis.nl. eng Case Reports Journal Article United States N Engl J Med 0255562 0028-4793 AIM IM Aged Fatal Outcome Heart Septal Defects, Ventricular diagnostic imaging etiology Heart Ventricles diagnostic imaging Humans Male Myocardial Infarction complications Ultrasonography 2016 6 9 6 0 2016 6 9 6 0 2016 6 22 6 0 ppublish 27276580 10.1056/NEJMicm1512579

2016 NEJM

196. Trends and Disparities in Acute Myocardial Infarction by County Income, 1999–2013 Full Text available with Trip Pro

Trends and Disparities in Acute Myocardial Infarction by County Income, 1999–2013 During the past decade, the incidence and mortality associated with acute myocardial infarction (AMI) in the United States have decreased substantially. However, it is unknown whether these improvements were consistent across communities of different economic status and geographic regions since efforts to improve cardiovascular disease prevention and management may have had variable impact.To determine whether

2016 JAMA cardiology

197. Usefulness of the Myocardial Infarction and Cardiac Arrest Calculator as a Discriminator of Adverse Cardiac Events After Elective Hip and Knee Surgery (Abstract)

Usefulness of the Myocardial Infarction and Cardiac Arrest Calculator as a Discriminator of Adverse Cardiac Events After Elective Hip and Knee Surgery The 2014 American College of Cardiology and American Heart Association guidelines on perioperative evaluation recommend differentiating patients at low risk (<1%) versus elevated risk (≥1%) for cardiac complications to guide appropriate preoperative testing. Among the tools recommended for estimating perioperative risk is the National Surgical (...) Quality Improvement Program (NSQIP) Myocardial Infarction and Cardiac Arrest (MICA) risk calculator. We investigated whether the NSQIP MICA risk calculator would accurately discriminate adverse cardiac events in a cohort of adult patients undergoing elective orthopedic surgery. We retrospectively reviewed 1,098 consecutive, elective orthopedic surgeries performed at Hershey Medical Center from January 1, 2013, to December 31, 2014. Adverse cardiac events were defined as myocardial infarction

2016 EvidenceUpdates

198. Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction (Abstract)

Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction Accurate risk stratification for contrast-induced nephropathy (CIN) is important for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We aimed to compare the prognostic value of validated risk scores for CIN. We prospectively

2016 EvidenceUpdates

199. Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction (Abstract)

Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction Patients with previous myocardial infarction (MI) have a high risk of recurrence. Little is known about the effectiveness of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in patients with a previous MI and left main or multivessel coronary artery disease (CAD). We compared long-term outcomes of these 2 strategies

2016 EvidenceUpdates Controlled trial quality: predicted high

200. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. Full Text available with Trip Pro

Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. To assess the risk of pulmonary embolism, ischaemic stroke, and myocardial infarction associated with combined oral contraceptives according to dose of oestrogen (ethinylestradiol) and progestogen.Observational cohort study.Data from the French national health insurance database linked with data from the French national hospital discharge (...) database.4 945 088 women aged 15-49 years, living in France, with at least one reimbursement for oral contraceptives and no previous hospital admission for cancer, pulmonary embolism, ischaemic stroke, or myocardial infarction, between July 2010 and September 2012.Relative and absolute risks of first pulmonary embolism, ischaemic stroke, and myocardial infarction.The cohort generated 5 443 916 women years of oral contraceptive use, and 3253 events were observed: 1800 pulmonary embolisms (33 per 100 000

2016 BMJ